Tatva Chintan Pharma Chem Ltd - 543321 - Board Meeting Intimation for Intimation Of The Board Meeting Scheduled To Be Held On Tuesday, 11.07.2023
Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/07/2023 ,inter alia, to consider and approve Fund Raising and other business transactions, as applicable. Tatva Chintan Pharma Chem Ltd - 543321 - Closure of Trading Window
Tatva Chintan Pharma Chem Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 Tatva Chintan Pharma Chem Ltd - 543321 - Intimation Of Schedule Of Plant Visit By Analyst / Investor On Wednesday, 28 June 2023.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company will be hosting a plant visit at Dahej SEZ Plant on Wednesday, 28 June 2023. No confidential / unpublished price sensitive information (UPSI) will be shared during the said plant visit. Please note that the above is subject to change, if any. The above information shall be uploaded on the website of the Company at www.tatvachintan.com. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Tatva Chintan Pharma Chem Ltd - 543321 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Submission of Annual Secretarial Compliance Report for the Financial Year ended 31 March 2023 (2022-23) Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 05 May 2023 post announcement of financial results of the Company for the quarter and financial year ended 31 March 2023. The above information shall be made available on Company's website of at www.tatvachintan.com. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring agency report of the Company for the quarter ended 31 March 2023, issued by ICICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering ('IPO') of the Company. The above information shall be made available on the website of the Company at www.tatvachintan.com. Tatva Chintan Pharma Chem Ltd - 543321 - Statement Of Deviation / Variation In Utilization Of Funds Raised Through IPO
Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 31 March 2023 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as at 31 March 2023, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021. Report issued by Monitoring agency report is being separately filed with the exchange. The above information shall be made available on the website of the Company at www.tatvachintan.com. Q4FY23 Quarterly & FY23 Annual Result Announced for Tatva Chintan Pharma Chem Ltd.
Specialty chemicals company Tatva Chintan Pharma Chem announced Q4FY23 & FY23 results: Q4FY23 vs Q4FY22: Revenue from operation: Rs 1,245.11 million vs Rs 985.31 million, up 26.37% YoY EBITDA (Excl. Other Income): Rs 162.74 million vs Rs 219.94 million, down 26.01% YoY EBITDA margin: 13.07% vs 22.32% Profit before tax: Rs 78.02 million vs Rs 189.76 million, down 58.88% YoY Profit after tax: Rs 169.54 million vs Rs 175.09 million, down 3.17% YoY PAT margin: 13.62% vs 17.77% FY23 vs FY22: Revenue from operation: Rs 4,236.12 million vs Rs 4,336.47 million, down 2.31% YoY EBITDA (Excl. Other Income): Rs 605.81 million vs Rs 1,082.35 million, down 44.03% YoY EBITDA margin: 14.30% vs 24.96% Profit before tax: Rs 447.79 million vs Rs 1,041.21 million, down 56.99% YoY Profit after tax: Rs 454.87 million vs Rs 958.74 million, down 52.56% YoY PAT margin: 10.74% vs 22.11% Commenting on the results, Chintan Shah, Managing Director, said, “Over the past decade, the Indian chemical sector had been growing rapidly. However, FY23 had been a roller coaster year for most of the chemical industries. Despite all geopolitical uncertainties, the Indian chemical industry showed good resilience. Many of the challenges are set to persist in 2023. Against a backdrop of fear of global recession and expectation of muted demand till H1FY24, Tatva Chintan continues to remain fairly optimistic about achieving reasonable growth. Most of the key raw material prices have dropped by 15%-25% which is also translating into reduced prices of the finished products. So, this becomes a big challenge for us to achieve revenue growth. Also due to muted global demand across most of the sectors, we are seeing continuous cost pressures coming from customers which would translate into slightly lower spreads on margins. I feel Tatva Chintan is fortunate with the timing of the launch of new products on a commercial scale during this financial year and also with the gradual rebound in the SDAs demand. Despite the challenging year ahead and even with the reduced product pricing we anticipate to grow by 20%-30% in FY24. Also, we anticipate slightly improving the EBITDA margins due to forecasted change in the product mix.” Result PDF